Japan Alport Syndrome Therapeutics Market Report 2023 to 2030

Japan Alport Syndrome Therapeutics Market Analysis

$ 3999

Japan during the forecast period of 2023-30, the Alport Syndrome therapeutics market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. Almost always affecting the kidney, Alport syndrome is a multisystem condition that also usually affects the inner ear and the eye. A variety of symptoms that normally start in childhood or adolescence and may get worse over time can be present. Invitae Corporation, Hoffmann-La Roche Ltd., Centogene N.V., and Eurofins Discovery are a few of the leading companies in the worldwide Alport syndrome market.

ID: IN10JPRD003 CATEGORY: Rare Diseases GEOGRAPHY: Japan AUTHOR: Gaurav Bhongale

Buy Now

Japan Alport Syndrome Therapeutics Market Analysis Summary

Japan Alport Syndrome Therapeutics Market is valued at around $10 Mn in 2022 and is projected to reach $17.97 Mn by 2030, exhibiting a CAGR of 7.6% during the forecast period 2023-2030.

In addition to kidney failure, hearing loss, and vision issues, Alport syndrome is an uncommon hereditary illness. Genes COL4A3, COL4A4, and COL4A5, which are important in the manufacture of proteins like type IV collagen, are mutated, and this disorder is the result. The number of Americans with this condition is less than 50,000.

Nerve deafness in various degrees was one of the most notable extrarenal symptoms mentioned by Alport. The diagnosis of the ailment is made using the patient's family history, clinical symptoms, and specialised testing, such as kidney biopsy. Genetic testing can formally establish the diagnosis. In addition to having nerve deafness, their urine also included blood and protein, however, the degree of these conditions varied between family members.

Increased mortality owing to end-stage disease was another characteristic of affected members.

The two Col4a5 models' X-linked nature predicts a gender skew in the disease's severity and course. Another autosomal kidney disorder with a sex-dependent pattern is polycystic kidney disease. More people with less severe types of Alport syndrome are being found, though, as research into the disorder continues. Future possibilities include exon skipping, chaperones, protein replacement therapy, genome editing, premature termination codon readthrough therapy, stem cell transplantation, and many more. In the ongoing proof-of-concept Phase 2 open-label clinical trial (NCT05448755) in up to eight Alport syndrome patients with nonsense mutations in the Collagen Type 4 genes, Eloxx has now dosed three patients with ELX-02 (COL4A3, COL4A4, and COL4A5). One patient's first decrease in proteinuria was encouraging. Increased prevalence and funding and adoption of home care settings have boosted the Alport Syndrome Therapeutics Market. Invitae Corporation, Hoffmann-La Roche Ltd., Centogene N.V., and Eurofins Discovery are a few of the leading companies in the worldwide Alport syndrome market.

Market Dynamics

Market Growth Drivers

Increased prevalence of syndrome: The COL4A5 gene, which is found on the X chromosome, has mutations that account for about 80% of instances of Alport syndrome. This contributes to the market's growth
Increased emphasis on diagnosis: Early indications of Alport syndrome are diagnosed using skin and kidney biopsies, and the faster adoption of these diagnostic methods is a key factor driving the global market
Increased funding on R&D: To encourage researchers and pharmaceutical companies to develop advanced medicines, the government is funding R&D initiatives
High adoption of home care settings: High adoption of home care settings has also encouraged the alport syndrome therapeutics market

Market Restraints

Companies are concentrating on clinical trials for the development of drugs for the disease because there is no particular treatment for Alport syndrome. The high expense of development is an additional difficulty.

Key players

Shire plc Pfizer Sanofi BioMarin Pharmaceutical Inc. Catalyst Biosciences Orchard Therapeutics plc uniQure Ionis Pharmaceuticals Alnylam Pharmaceuticals PTC Therapeutics Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

??Japan Alport Syndrome Therapeutics Market Segmentation

Genetic Type

X-linked Alport Syndrome
Autosomal Recessive Alport Syndrome
Autosomal Dominant Alport Syndrome
Others

Diagnosis

Urine analysis
Creatinine clearance test
GFR estimation
Kidney biopsy
Genetic testing
Ear examination
Eye examination

Treatment

Medication
ACE Inhibitors
Angiotensin -II receptor blockers
Sodium-glucose transport type 2 inhibitor
RAAS inhibition
Others
Surgery
Dietary control
Others

End-Users

Hospitals
Specialty Clinics
Others

Distribution Channel

Hospitals
Pharmacy
Others

Route of Administration

Oral
Parenteral
Others

Dosage form

Tablet
Capsule
Injectables
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.